|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||29.02 - 29.69|
|52 Week Range||28.54 - 31.85|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.70%|
As we’ve already seen, Johnson & Johnson reported revenues of ~$20.2 billion in 4Q17, an 11.5% growth in revenues compared to ~$18.1 billion in 4Q16. Analysts also estimate that Johnson & Johnson could generate EPS (earnings per share) of $2.01 on revenues of ~$19.4 billion in 1Q18, a 9.2% growth compared to 1Q17. Analyst recommendations show a 12-month target price of $150.62 per share compared to its last price of $132.02 per share on February 23, 2018.
First Trust has come a long way since its foray into the exchange traded fund universe more than a decade ago.
On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros. Ablynx and Sanofi had a successful existing partnership for multiple sclerosis research and immunoinflammatory diseases. Under the agreement terms, Sanofi gained access Ablynx’s scientists, certain nanobodies in its product portfolio, and Ablynx’s proprietary nanobody platform.
GlaxoSmithKline (GSK) estimates the global incidence of MM to be close to 124,000 with 30,000 patients in the US, 27,000 in EU5, and around 8,000 in Japan. The above diagram shows that despite the advent of multiple new treatment options from companies like Celgene (CELG), Johnson & Johnson (JNJ), and Amgen (AMGN), the five-year survival rate for MM patients continues to be below 50%. In 2016, the global market value of MM was around $12 billion, a year-over-year (or YoY) rise of 40%.
In 3Q17, Novartis’s COPD (Chronic Obstructive Pulmonary Disorder) portfolio reported revenues of $165 million, which with ~2% higher YoY and 1% higher QoQ.
Income investors looking for stocks that have achieved dividend achievers status do not need to confine their search to large-cap equities. A new exchange traded fund from First Trust provides a basket ...
This series will discuss the top ten aerospace and defense products and services companies based on their dividend yields.
First Trust Advisors L.P. announces the declaration of distributions for 116 exchange-traded funds advised by FTA.
In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.
Three analysts were analyzing Novartis in September 2017. One analyst recommended a “strong buy,” while the other two recommended a “hold.”
FMC Technologies and Technip merged to become TechnipFMC (FTI) in 2017, an international provider of subsea, onshore, offshore, and surface projects. The synergy aims to combat the challenges of low oil…...
GlaxoSmithKline (GSK) reported revenues of 7.32 billion pounds in 2Q17—12% growth compared to revenues of 6.53 billion pounds in 2Q16.
Novartis (NVS) reported flat revenues of $12.24 billion on a constant-currency basis for 2Q17. This included a 2% decline due to foreign exchange.
Bristol-Myers Squibb (BMY) met Wall Street analysts’ estimate for EPS at $0.74. It also surpassed the estimates for revenues.
Sanofi’s (SNY) generic business contributed ~5.1% of its total revenue in 2Q17. The business reported revenue of 442 million euros in 2Q17, an 8% decrease from 2Q16. Revenue fell due…
Sanofi (SNY), one of the world's largest pharmaceutical companies, reported operational growth of 5.5% to reach revenue of 8.7 billion euros in 2Q17.